Journal ArticleDOI
High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.
Sadaf Altaf,Felicity Enders,Elysia N. Jeavons,Mark Krailo,Donald A. Barkauskas,Paul A. Meyers,Carola A.S. Arndt +6 more
TLDR
The effect of BMI at diagnosis on therapy related toxicities and outcome in pediatric osteosarcoma patients treated on Children's Oncology Group (COG) trial INT0133 was analyzed.Abstract:
Background
Body mass index (BMI), at diagnosis has been associated with lower survival and increased toxicity in cancer patients. We analyzed the effect of BMI at diagnosis on therapy related toxicities and outcome in pediatric osteosarcoma patients treated on Children's Oncology Group (COG) trial INT0133.
Procedures
All patients enrolled on COG-INT0133 with height, weight and toxicity information were eligible. BMI was expressed as age and gender specific percentiles using height and weight at diagnosis. Patients were classified into high, normal and low BMI groups. Logistic regression models were used to analyze toxicities; Kaplan–Meier curves were created to assess event free (EFS) and overall survival (OAS).
Results
Seven hundred and ten patients met eligibility criteria. BMI distribution was: 447 normal BMI, 74 low BMI, and 189 high BMI. Renal toxicity was higher in the high BMI group (OR = 2.7, 95% CI 1.2–6.4, P = 0.01) only during one of the courses of therapy. Compared to the normal BMI group, patients with high BMI had significantly worse OAS at 5 years compared to those with normal BMI, 69.7% versus 80.5% (HR = 1.6, 95% CI 1.1–2.2, P = 0.005) and a trend towards worse event-free survival at 3 years 66.2% versus 75.5% (HR = 1.3 95% CI 0.9–1.8, P = 0.05). There was no difference in EFS or OAS in patients with low BMI compared to patients with normal BMI.
Conclusions
High BMI at diagnosis is associated with worse OAS in patients with osteosarcoma. No clinically significant differences in toxicity were observed in the various BMI groups. Pediatr Blood Cancer 2013;60:2042–2046. © 2013 Wiley Periodicals, Inc.read more
Citations
More filters
Journal ArticleDOI
UK guidelines for the management of bone sarcomas
Craig Gerrand,Nicholas A. Athanasou,Bernadette Brennan,Robert J. Grimer,Ian Judson,Bruce Morland,David Peake,Beatrice Seddon,Jeremy Whelan +8 more
TL;DR: This document is an update of the British Sarcoma Group guidelines and recommends that patients with clinico-radiological findings suggestive of a primary bone tumour at any site in the skeleton should be referred to a specialist centre and managed by a fully accredited bone sarcoma multidisciplinary team.
Journal ArticleDOI
Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature.
TL;DR: Existing literature supports the prognostic significance of NS in pediatric solid tumor patients and underscores the need for prospective studies to better elucidate underlying physiological changes in this population.
Journal ArticleDOI
Platinum-induced hearing loss after treatment for childhood cancer.
TL;DR: The existing evidence on the association between childhood cancer treatment including platinum analogues and the occurrence of hearing loss was evaluated to develop less ototoxic treatment protocols for the future treatment of children with cancer and to develop adequate follow-up protocols for childhood cancer survivors treated with platinum-based therapy.
Journal ArticleDOI
Association between Body Condition Score and Cancer Prognosis in Dogs with Lymphoma and Osteosarcoma
TL;DR: Obesity was not associated with adverse outcomes among dogs with LSA or OSA in this retrospective study; however, being underweight at the time of diagnosis of LSA was associated with shorter survival.
References
More filters
Journal Article
Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Jean-Philippe Bastard,Mustapha Maachi,Claire Lagathu,Minji Kim,Martine Caron,Hubert Vidal,Jacqueline Capeau,Bruno Fève +7 more
TL;DR: It can be considered that obesity corresponds to a sub-clinical inflammatory condition that promotes the production of pro-inflammatory factors involved in the pathogenesis of insulin resistance, including leptin, TNF-alpha, IL-6 and resistin.
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Journal Article
Changes in terminology for childhood overweight and obesity.
TL;DR: The terminology used for high BMI-for-age in children in the United States to date has been based on the recommendation of an expert committee convened by federal agencies, and changes in terminology were proposed.
Journal ArticleDOI
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Jennifer J. Griggs,Pamela B. Mangu,Holly Anderson,Edward P. Balaban,James J. Dignam,William Hryniuk,Vicki A. Morrison,T. May Pini,Carolyn D. Runowicz,Gary L. Rosner,Michelle Shayne,Alex Sparreboom,Lara Sucheston,Gary H. Lyman +13 more
TL;DR: Full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure, and the use of fixed-dose chemotherapy is rarely justified.
Related Papers (5)
The Impact of Preoperative Low Body Mass Index on Postoperative Complications and Long-term Survival Outcomes in Gastric Cancer Patients.
Low and high body mass index in hidradenitis suppurativa patients—different subtypes?
P. Theut Riis,Ditte Marie Saunte,Farida Benhadou,V. Del Marmol,Philippe Guillem,Moetaz El-Domyati,Hossam Abdel-Wahab,Ch. Antoniou,Clio Dessinioti,Mehmet Ali Gürer,Burcu Beksaç,Jacek C Szepietowski,Lukasz Matusiak,Lennart Emtestam,Jan Lapins,H. Riad,N. Doss,A. F. Massa,Iltefat H. Hamzavi,C. Nicholson,M. Dolenc-Voljc,M. Dolenc-Voljc,Kyu Han Kim,Kyu Han Kim,Jungyoon Ohn,Jungyoon Ohn,Christos C. Zouboulis,Ioannis Karagiannidis,Z. B. Mokos,P. Durinec,Gregor B.E. Jemec +30 more